1492 Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

1492 Capital Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$312K	Buy	50,705 +22,613	+80%	+$175K	0.12%	103
2025 Q4	$216K	Buy	+28,092	New	+$231K	0.08%	107
2023 Q2	–	Sell	-94,839	Closed	-$789K	–	104
2023 Q1	$789K	Sell	94,839 -31	-0%	-$288	0.49%	64
2022 Q4	$911K	Buy	+94,870	New	+$839K	0.59%	55

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

1492 Capital Management's FENC Position: Q1 2026 in Review

1492 Capital Management increased its Fennec Pharmaceuticals (FENC) stake by 80% in Q1 2026, buying an estimated $175K and bringing the position to 50,705 shares worth $312K. The position accounts for 0.12% of the portfolio, ranked #103.

1492 Capital Management first reported a position in FENC in Q4 2022 and has held it in 4 quarters since. The position peaked at $911K in Q4 2022. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

1492 Capital Management held 50,705 shares of Fennec Pharmaceuticals worth $312K as of Q1 2026.
1492 Capital Management bought 22,613 Fennec Pharmaceuticals shares in Q1 2026, an estimated $175K.
Fennec Pharmaceuticals made up 0.12% of 1492 Capital Management's portfolio in Q1 2026, its #103 holding.
1492 Capital Management first reported a position in Fennec Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
1492 Capital Management's Fennec Pharmaceuticals position peaked at $911K in Q4 2022.
90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.